Skip to main content

Table 1 Patients’ characteristics

From: Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study

   Oral vinorelbine dose arms
   30 mg 40 mg 50 mg
Patients N 27 24 22
Age median 67 66 67
  range 43-74 48-75 44-75
Gender Male 18 (66.6%) 17 (70.8%) 15 (68.2%)
  Female 9 (33.4%) 7 (29.2%) 7 (31.8)
Cancer type Breast 7 (26.0%) 6 (25.0%) 7 (31.8%)
  Prostate 8 (29.6%) 7 (29.2%) 7 (31.8%)
  NSCLC 12 (44.4%) 11 (45.8%) 8 (36.4%)
PS 0 8 (29.6%) 10 (41.6%) 8 (36.4%)
  1 15 (55.6%) 11 (45.8%) 12 (54.6%)
  2 4 (14.8%) 3 (12.6%) 2 (9.0%)
Prior chemotherapy 0 5 (18.6%) 4 (16.6%) 5 (22.8%)
  1 13 (48.2%) 12 (50.0%) 11 (50.0%)
  2 9 (33.4%) 8 (33.4%) 6 (27.2%)
Prior radiotherapy   14 (51.8%) 8 (33.4%) 11 (50.0%)
Prior hormonotherapy   12 (44.4%) 11 (44.8%) 13 (59.0%)
Organs with metastases lung 15 (55.6%) 14 (58.4%) 10 (45.4%)
  liver 8 (29.6%) 4 (16.6%) 3 (13.6%)
  bone 18 (66.6%) 15 (62.6%) 9 (41%)